JBM (Healthcare) (HKG:2161) unit Arrow King agreed to acquire a 90% equity stake in Tin Hee Tong Medicine Factory from Hou Jiasheng for HK$171 million, a Feb. 21 filing with the Hong Kong bourse said.
Following completion, Yang QiCheng David, who owns the remaining 10% shares in Tin Hee Tong Medicine Factory will enter into a right of first refusal contract with the buyer.
Under the agreement, if Yang plans to dispose of part or all of his stake in the target, he will first offer to sell the shares to the Arrow King.
Tin Hee Tong Medicine Factory engages mainly in the manufacture, marketing, and sales of proprietary Chinese medicine Tin Hee Tong Tin Hee Pills.
The acquisition will allow the medicine distributor to expand its portfolio of proprietary Chinese medicines and accelerate its growth strategies.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。